Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Recharge & Recaffeinate with Sidley @ JPMMonday, January 12, 2026 – Tuesday, January 13, 2026Biotech Dealmaking – Regulatory Considerations for the Next Wave of Development-Stage Transactions – Program and Lunch @ JPM 2026Monday, January 12, 2026Sidley Advises Lux Capital on New VC Fund Lux IXJanuary 9, 2026Top Posts of 2025January 8, 2026Sidley Represented Bessemer Investors in Sale of Leonard Valve CompanyJanuary 7, 2026Bloomberg Ranks Sidley No. 1 for Shareholder Activism Defense for 6th Year in a Row With Record Number of CampaignsJanuary 5, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory